In vivo stability evaluation of Mg substituted low crystallinity ß-tricalcium phosphate granules fabricated through dissolution-precipitation reaction for bone regeneration

Garima Tripathi, Yuki Sugiura, Kanji Tsuru, Kunio Ishikawa

Research output: Contribution to journalArticle

Abstract

Although β-tricalcium phosphate (β-TCP) is widely used in clinical applications as a bone substitute owing to its positive tissue response and its ability to be replaced by new bone through a bone-remodeling process, it has the limitation of rapid resorption in vivo, which might become a reason for tissue atrophy and high crystallinity, which decrease biocompatibility. A reduction in the crystallinity might increase the biocompatibility of the bone substitute. To overcome the drawbacks of β-TCP, decrease in crystallinity and solubility, both are required. Therefore, in this study, the feasibility of fabricating Mg substituted low crystalline β-TCP (Mg-LC-β-TCP) granules formed in aqueous solution was evaluated in vivo focusing long-term adsorption and bone formation in bone defects formed in the rabbit femur using sintered β-TCP granules as a control. With Mg-LC-β-TCP, the resorption of the substitute was suppressed, and no tissue atrophy was observed even at 24 weeks post-implantation, whereas a few granules with surrounding tissue atrophy were observed at 12 weeks post-implantation. Tartrate-resistant acid phosphatase-staining indicated that the density of osteoclasts type cells with Mg-LC-β-TCP was significantly lower than that with β-TCP, and also the numbers of osteoblasts type cells with Mg-LC-β-TCP were significantly higher than that with β-TCP. It is suggested that Mg substitution to form low crystallinity β-TCP is a valuable way to overcome the limitations of β-TCP as a bone substitute.

Original languageEnglish
Article number065002
JournalBiomedical Materials (Bristol)
Volume13
Issue number6
DOIs
Publication statusPublished - Aug 15 2018

Fingerprint

Bone
Dissolution
Phosphates
Bone Substitutes
Crystalline materials
Tissue
Biocompatibility
Osteoblasts
Acid Phosphatase
Substitution reactions
Phosphatases
Solubility
tricalcium phosphate
Adsorption
Defects
Acids

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

@article{01740d3fe259417ea6307bb475809fc1,
title = "In vivo stability evaluation of Mg substituted low crystallinity {\ss}-tricalcium phosphate granules fabricated through dissolution-precipitation reaction for bone regeneration",
abstract = "Although β-tricalcium phosphate (β-TCP) is widely used in clinical applications as a bone substitute owing to its positive tissue response and its ability to be replaced by new bone through a bone-remodeling process, it has the limitation of rapid resorption in vivo, which might become a reason for tissue atrophy and high crystallinity, which decrease biocompatibility. A reduction in the crystallinity might increase the biocompatibility of the bone substitute. To overcome the drawbacks of β-TCP, decrease in crystallinity and solubility, both are required. Therefore, in this study, the feasibility of fabricating Mg substituted low crystalline β-TCP (Mg-LC-β-TCP) granules formed in aqueous solution was evaluated in vivo focusing long-term adsorption and bone formation in bone defects formed in the rabbit femur using sintered β-TCP granules as a control. With Mg-LC-β-TCP, the resorption of the substitute was suppressed, and no tissue atrophy was observed even at 24 weeks post-implantation, whereas a few granules with surrounding tissue atrophy were observed at 12 weeks post-implantation. Tartrate-resistant acid phosphatase-staining indicated that the density of osteoclasts type cells with Mg-LC-β-TCP was significantly lower than that with β-TCP, and also the numbers of osteoblasts type cells with Mg-LC-β-TCP were significantly higher than that with β-TCP. It is suggested that Mg substitution to form low crystallinity β-TCP is a valuable way to overcome the limitations of β-TCP as a bone substitute.",
author = "Garima Tripathi and Yuki Sugiura and Kanji Tsuru and Kunio Ishikawa",
year = "2018",
month = "8",
day = "15",
doi = "10.1088/1748-605X/aad385",
language = "English",
volume = "13",
journal = "Biomedical Materials (Bristol)",
issn = "1748-6041",
publisher = "IOP Publishing Ltd.",
number = "6",

}

TY - JOUR

T1 - In vivo stability evaluation of Mg substituted low crystallinity ß-tricalcium phosphate granules fabricated through dissolution-precipitation reaction for bone regeneration

AU - Tripathi, Garima

AU - Sugiura, Yuki

AU - Tsuru, Kanji

AU - Ishikawa, Kunio

PY - 2018/8/15

Y1 - 2018/8/15

N2 - Although β-tricalcium phosphate (β-TCP) is widely used in clinical applications as a bone substitute owing to its positive tissue response and its ability to be replaced by new bone through a bone-remodeling process, it has the limitation of rapid resorption in vivo, which might become a reason for tissue atrophy and high crystallinity, which decrease biocompatibility. A reduction in the crystallinity might increase the biocompatibility of the bone substitute. To overcome the drawbacks of β-TCP, decrease in crystallinity and solubility, both are required. Therefore, in this study, the feasibility of fabricating Mg substituted low crystalline β-TCP (Mg-LC-β-TCP) granules formed in aqueous solution was evaluated in vivo focusing long-term adsorption and bone formation in bone defects formed in the rabbit femur using sintered β-TCP granules as a control. With Mg-LC-β-TCP, the resorption of the substitute was suppressed, and no tissue atrophy was observed even at 24 weeks post-implantation, whereas a few granules with surrounding tissue atrophy were observed at 12 weeks post-implantation. Tartrate-resistant acid phosphatase-staining indicated that the density of osteoclasts type cells with Mg-LC-β-TCP was significantly lower than that with β-TCP, and also the numbers of osteoblasts type cells with Mg-LC-β-TCP were significantly higher than that with β-TCP. It is suggested that Mg substitution to form low crystallinity β-TCP is a valuable way to overcome the limitations of β-TCP as a bone substitute.

AB - Although β-tricalcium phosphate (β-TCP) is widely used in clinical applications as a bone substitute owing to its positive tissue response and its ability to be replaced by new bone through a bone-remodeling process, it has the limitation of rapid resorption in vivo, which might become a reason for tissue atrophy and high crystallinity, which decrease biocompatibility. A reduction in the crystallinity might increase the biocompatibility of the bone substitute. To overcome the drawbacks of β-TCP, decrease in crystallinity and solubility, both are required. Therefore, in this study, the feasibility of fabricating Mg substituted low crystalline β-TCP (Mg-LC-β-TCP) granules formed in aqueous solution was evaluated in vivo focusing long-term adsorption and bone formation in bone defects formed in the rabbit femur using sintered β-TCP granules as a control. With Mg-LC-β-TCP, the resorption of the substitute was suppressed, and no tissue atrophy was observed even at 24 weeks post-implantation, whereas a few granules with surrounding tissue atrophy were observed at 12 weeks post-implantation. Tartrate-resistant acid phosphatase-staining indicated that the density of osteoclasts type cells with Mg-LC-β-TCP was significantly lower than that with β-TCP, and also the numbers of osteoblasts type cells with Mg-LC-β-TCP were significantly higher than that with β-TCP. It is suggested that Mg substitution to form low crystallinity β-TCP is a valuable way to overcome the limitations of β-TCP as a bone substitute.

UR - http://www.scopus.com/inward/record.url?scp=85055469538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055469538&partnerID=8YFLogxK

U2 - 10.1088/1748-605X/aad385

DO - 10.1088/1748-605X/aad385

M3 - Article

VL - 13

JO - Biomedical Materials (Bristol)

JF - Biomedical Materials (Bristol)

SN - 1748-6041

IS - 6

M1 - 065002

ER -